Datar Cancer Genetics Unveils Exacta AI: A Revolutionary AI-Driven Cancer Treatment Platform

Metropolis Healthcare Partners with Roche to Launch Self-Sampling HPV DNA Test for Cervical Cancer Screening in India

Union Budget 2025: Full Exemption from Basic Customs Duty (BCD) for 36 Lifesaving Drugs

Dr. Jitendra Singh Inaugurates Centre for Advanced Genomics & Precision Medicine at AIIMS Jammu

Union Budget 2025-26: Key Healthcare Measures for Cancer Care and Access to Life-Saving Drugs

FDA Approves Roche’s PATHWAY HER2 Test for Identifying HER2-Ultralow Breast Cancer Patients Eligible for ENHERTU

Bristol Myers Squibb’s Breyanzi® Receives CHMP Recommendation for Relapsed or Refractory Follicular Lymphoma in the EU

NHS to Offer Groundbreaking Gene Therapy for Sickle Cell Disease

Quibim Secures $50M Series A to Advance AI-Powered Imaging for Precision Medicine

Apollo Hospitals Unveils Advanced Oncology Facility in Chennai

Beckman Coulter’s Alzheimer’s Blood Test Receives FDA Breakthrough Device Designation

ANGLE Announces Breakthrough Dual CTC-DNA and ctDNA Analysis with Illumina’s NGS Solution

Diatech Pharmacogenetics and Merck Expand Collaboration to Enhance RAS Biomarker Testing in MEA Region

DCG Unveils AI-Powered Video-Reporting for Personalized Chemotherapy Selection

FDA Approves Monthly Maintenance Dosing for LEQEMBI® in Alzheimer’s Treatment

Home
/
update
/
details

Dedication Ceremony by President Droupadi Murmu for CAR-T Cell Therapy at IIT Bombay

NextEdge Admin

04 Apr 2024

1 min 52 sec

CAR T-Cell therapy,Dr. Gaurav Narula,Indian Institute of Technology (IIT) Bombay

President Droupadi Murmu is poised to inaugurate India’s groundbreaking CAR T-Cell therapy for advanced blood cancer treatment at the Indian Institute of Technology (IIT) Bombay, Powai campus on April 4. This milestone offers hope to Indian patients by providing the therapy at a significantly reduced cost of ₹40 lakh, a stark contrast to the exorbitant ₹5 crore expense in the US, making it accessible to many.

CAR T-Cell therapy, a personalized treatment, differs from chemotherapy as it is tailored to individual patients. Spearheaded by Dr. Gaurav Narula, a pediatric hematologist-oncologist at Tata Hospital, and Dr. Rahul Purwar, a faculty member at IIT-Bombay, Powai, the initiative introduces a novel CAR T-Cell therapy capable of prolonged circulation within the body. This innovative approach holds the promise of long-term cancer remission without requiring a bone marrow transplant.

In this therapy, the patient’s blood is utilized to isolate T-cells, which are then genetically modified in the lab to produce cancer-fighting cells called CAR-T cells expressing chimeric antigen receptors (CARs) specific to cancer cells. These modified cells are reintroduced into the patient, designed to seek out and eliminate cancer cells in the body.